Effectiveness of Nicotine Replacement Therapy on Smoking Cessation and Reduction Among Pulmonary Tuberculosis Patients - A Randomized Controlled Trial

被引:0
|
作者
Purushothama, Jagannath [1 ]
Badiger, Sanjeev [2 ]
Olickal, Jeby J. [1 ]
Kunkulol, Rahul [3 ]
Kumar, Nanjesh [4 ]
D'Souza, Neevan [4 ]
机构
[1] Nitte, K S Hegde Med Acad, Dept Publ Hlth, Mangaluru, Karnataka, India
[2] A J Inst Med Sci & Res Ctr, Dept Community Med, Mangaluru, Karnataka, India
[3] Pravara Inst Med Sci, Dept Pharmacol, Loni, Maharashtra, India
[4] Nitte, K S Hegde Med Acad, Dept Community Med, Mangaluru, Karnataka, India
关键词
Nicotine; pulmonary; randomized controlled trial; therapeutics; tobacco cessation; tuberculosis;
D O I
10.4103/ijpvm.ijpvm_3_22
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background': India is ranked second in the world in terms of tobacco use and tops the list of eight high-burden countries that account for two-thirds of the new tuberculosis (TB) cases globally. As tobacco smoking among TB patients is associated with unsuccessful TB treatment outcomes, effective smoking cessation interventions for TB patients is essential to combat this double pandemic. Aim: The study determined the effectiveness of nicotine replacement therapy (NRT) on smoking reduction and cessation among pulmonary TB patients. Settings and Design: The study included 300 pulmonary TB patients undergoing antitubercular treatment in government health care centers of Dakshina Kannada district in southern India. Materials and Methods: The participants in this two-armed, single-blinded, placebo-controlled, block-randomized trial were divided equally (n = 150) for experimental arm (brief advice + NRT) and control arm (brief advice + placebo). The total duration of treatment and follow-up was 6 months. Unadjusted relative risk (URR) and adjusted relative risk (ARR) were calculated for treatment outcomes at 95% confidence interval (CI). Generalized linear regression analysis was performed upon variables with P value less than 0.2. Results: After 6 months of intervention including follow up, there was a significant reduction in self-reported smoking (ARR = 1.08, 95% CI 1.01-1.17, P = 0.03) in the experimental arm compared with the control arm. Biochemically verified smoking abstinence was not significantly different between the two arms (ARR = 1.01, 95% CI 0.72-1.38, P = 0.97). Conclusion: The study showed statistically significant effectiveness of NRT for self-reported smoking reduction.
引用
收藏
页数:6
相关论文
共 50 条
  • [41] Nicotine replacement therapy for smoking cessation (Review)
    Stead, L. F.
    Perera, R.
    Mant, D.
    Lancaster, T.
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2008, (01):
  • [42] Cost-Effectiveness of Nicotine Patches for Smoking Cessation in Pregnancy: A Placebo Randomized Controlled Trial (SNAP)
    Essex, Holly N.
    Parrott, Steve
    Wu, Qi
    Li, Jinshuo
    Cooper, Sue
    Coleman, Tim
    [J]. NICOTINE & TOBACCO RESEARCH, 2015, 17 (06) : 636 - 642
  • [43] Factors Associated With Smoking Cessation in Early and Late Pregnancy in the Smoking, Nicotine, and Pregnancy Trial: A Trial of Nicotine Replacement Therapy
    Vaz, Luis R.
    Leonardi-Bee, Jo
    Aveyard, Paul
    Cooper, Sue
    Grainge, Matthew
    Coleman, Tim
    [J]. NICOTINE & TOBACCO RESEARCH, 2014, 16 (04) : 381 - 389
  • [44] Lack of association of 5-HTTLPR genotype with smoking cessation in a nicotine replacement therapy randomized trial
    Munafò, MR
    Johnstone, EC
    Wileyto, EP
    Shields, PG
    Elliot, KM
    Lerman, C
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2006, 15 (02) : 398 - 400
  • [45] Monthly Motivational Interview Counseling and Nicotine Replacement Therapy for Smoking Parents of Pediatric Patients: A Randomized Controlled Trial
    Dai, Siyu
    Chan, Michael Ho Ming
    Kam, Richard Kin Ting
    Li, Albert Martin
    Au, Chun Ting
    Chan, Kate Ching-Ching
    [J]. FRONTIERS IN PEDIATRICS, 2022, 10
  • [46] Pre-cessation nicotine replacement therapy: pragmatic randomized trial
    Bullen, Chris
    Howe, Colin
    Lin, Ruey-Bin
    Grigg, Michele
    Laugesen, Murray
    McRobbie, Hayden
    Glover, Marewa
    Walker, Natalie
    Wallace-Bell, Mark
    Whittaker, Robyn
    Rodgers, Anthony
    [J]. ADDICTION, 2010, 105 (08) : 1474 - 1483
  • [47] Varenicline Combined With Oral Nicotine Replacement Therapy and Smartphone-Based Medication Reminders for Smoking Cessation: Feasibility Randomized Controlled Trial
    Sifat, Munjireen
    Hebert, Emily
    Ahluwalia, Jasjit S.
    Businelle, Michael S.
    Waring, Joseph J. C.
    Frank-Pearce, Summer G.
    Bryer, Chase
    Benson, Lizbeth
    Madison, Stefani
    Planas, Lourdes G.
    Baranskaya, Irina
    Kendzor, Darla E.
    [J]. JMIR FORMATIVE RESEARCH, 2023, 7
  • [48] Does improved access and greater choice of nicotine replacement therapy affect smoking cessation success? Findings from a randomized controlled trial
    Walker, Natalie
    Howe, Colin
    Bullen, Chris
    Grigg, Michele
    Glover, Marewa
    McRobbie, Hayden
    Laugesen, Murray
    Jiang, Joy
    Chen, Mei-Hua
    Whittaker, Robyn
    Rodgers, Anthony
    [J]. ADDICTION, 2011, 106 (06) : 1176 - 1185
  • [49] Comparison between cytisine and Nicotine Replacement Therapy in smoking cessation among inpatient psychiatric patients
    Tavakoli-Ardakani, Maria
    Sani, Zeinab Gholamzadeh
    Beyraghi, Narges
    Najarimoghadam, Shadi
    Kheradmand, Ali
    [J]. JOURNAL OF ADDICTIVE DISEASES, 2023,
  • [50] Effectiveness, safety and cost-effectiveness of vaporized nicotine products versus nicotine replacement therapy for tobacco smoking cessation in a low-socioeconomic status Australian population: a study protocol for a randomized controlled trial
    Howard, Bridget C.
    McRobbie, Hayden
    Petrie, Dennis
    Barker, Daniel
    Mendelsohn, Colin
    Anderson, Jack
    Borland, Ron
    Naughton, Felix
    Tutka, Piotr
    Zwar, Nick
    Boland, Veronica C.
    Aiken, Alexandra
    Shakeshaft, Anthony
    Gartner, Coral
    Richmond, Robyn L.
    Hall, Wayne
    Mattick, Richard P.
    Farrell, Michael
    Courtney, Ryan J.
    [J]. TRIALS, 2022, 23 (01)